GlassScriptPhysician profile
Bo Zhao
NPI 1245464742
$5,725.21
in general payments reported to CMS, 2019-2025
31 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $1,545 · 2021: $148 · 2022: $294 · 2023: $532 · 2024: $359 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,283 · Food and Beverage: $1,141 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,282.50 |
| Food and Beverage | $1,141.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $107.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,668.05 | 2020-2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $1,297.47 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.26 | 2023-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $365.26 | 2019-2025 | Keytruda |
| Amgen INC. | $262.82 | 2019 | |
| Array Biopharma INC | $150.00 | 2025 | Braftovi, Lorbrena, Mektovi |
| Blueprint Medicines Corporation | $142.23 | 2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $130.80 | 2024 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $123.30 | 2019-2020 | |
| Coherus Oncology, INC. | $121.44 | 2022 | |
| Janssen Biotech, INC. | $116.63 | 2019-2020 | |
| Astellas Pharma US INC | $115.11 | 2019-2024 | |
| Tempus Ai, INC | $92.95 | 2025 | Xt Cdx |
| Incyte Corporation | $91.46 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84.68 | 2019-2023 | Tecentriq |
| Seagen INC. | $52.44 | 2022 | |
| Emd Serono, INC. | $51.48 | 2019 | |
| Genzyme Corporation | $46.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.08 | 2019-2022 | |
| Heron Therapeutics, INC. | $23.51 | 2019 | |
| Pfizer INC. | $22.01 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.67 | 2019 | |
| Sanofi US Services INC. | $18.87 | 2025 | |
| Eisai INC. | $18.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Exelixis INC. | $13.56 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.